WO2021039748A1 - ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 - Google Patents

ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 Download PDF

Info

Publication number
WO2021039748A1
WO2021039748A1 PCT/JP2020/031917 JP2020031917W WO2021039748A1 WO 2021039748 A1 WO2021039748 A1 WO 2021039748A1 JP 2020031917 W JP2020031917 W JP 2020031917W WO 2021039748 A1 WO2021039748 A1 WO 2021039748A1
Authority
WO
WIPO (PCT)
Prior art keywords
aqueous ophthalmic
ophthalmic composition
diquafosol
polyvinylpyrrolidone
sodium
Prior art date
Application number
PCT/JP2020/031917
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
健司 森島
博之 浅田
雄介 桃川
明日香 神村
健一 遠藤
Original Assignee
参天製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 参天製薬株式会社 filed Critical 参天製薬株式会社
Priority to KR1020247011257A priority Critical patent/KR20240049646A/ko
Priority to JP2021521065A priority patent/JP6966667B2/ja
Priority to CN202311818685.6A priority patent/CN117771172A/zh
Priority to KR1020227009546A priority patent/KR102656181B1/ko
Priority to CN202080059970.2A priority patent/CN114286670B/zh
Publication of WO2021039748A1 publication Critical patent/WO2021039748A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • the present invention relates to an aqueous ophthalmic composition containing diquafosol or a salt thereof, and polyvinylpyrrolidone.
  • (B-1) An ophthalmic pharmaceutical product in which 0.1 to 1 mL of an aqueous ophthalmic composition used for prevention or treatment of dry eye is filled in a unit dose type eye drop container, and the aqueous ophthalmic composition is It contains 3% (w / v) concentration of diquafosol sodium and polyvinylpyrrolidone having a K value of 90, and is characterized by being used so as to be instilled 1 to 2 drops at a time and 2 to 4 times a day. Ophthalmic pharmaceutical products.
  • the use of the substance is characterized in that 1 to 10 mL of the aqueous ophthalmic composition is filled in a PFMD container and used so as to be instilled 1 to 2 drops at a time and 2 to 4 times a day.
  • (C-7) Any of (C-1) to (C-6), wherein the aqueous ophthalmic composition is used by instilling 1 to 2 drops at a time, 3 times a day. Use of the aqueous ophthalmic composition according to 1.
  • this composition Since this composition has a high tear volume increasing effect, a stronger dry eye therapeutic effect is expected as compared with the case of instillation of existing Diquas (registered trademark) ophthalmic solution. Therefore, it is also expected that this composition exerts a dry eye therapeutic effect comparable to or higher than that of the existing Diquas (registered trademark) ophthalmic solution at a lower concentration.
  • the existing Diquas (registered trademark) ophthalmic solution needs to be instilled 6 times a day, and although there are some patients who do not obtain the expected effect due to poor eye drop adherence, polyvinylpyrrolidone having a certain K value.
  • the silver salt is stable and exhibits excellent preservative effect.
  • CMC-Na sodium carboxymethyl cellulose
  • HPMC hydroxypropylmethyl cellulose
  • CVP carboxyvinyl polymer
  • diquafosol ophthalmic solution means an aqueous ophthalmic solution containing diquafosol or a salt thereof.
  • the “salt of diquafosol” is not particularly limited as long as it is a pharmaceutically acceptable salt, and is a metal salt with lithium, sodium, potassium, calcium, magnesium, zinc, etc .; hydrochloric acid, hydrobromic acid, hydroiodide.
  • diquafosol or a salt thereof also includes a hydrate and an organic solvate of diquafosol (free form) or a salt thereof.
  • diquafosol or salt thereof is preferably a sodium salt of diquafosol, and a diquafosol tetrasodium salt represented by the following chemical structural formula (also simply referred to as "diquafosol sodium" in the present specification) is particularly preferable. preferable.
  • polyvinylpyrrolidone K17 polyvinylpyrrolidone K25, polyvinylpyrrolidone K30, polyvinylpyrrolidone K40, polyvinylpyrrolidone K50, polyvinylpyrrolidone K60, polyvinylpyrrolidone K70, polyvinylpyrrolidone K80, polyvinylpyrrolidone K85, polyvinylpyrrolidone K90, polyvinylpyrrolidone K120 and the like can be mentioned.
  • ⁇ rel is the relative viscosity of the polyvinylpyrrolidone aqueous solution with respect to water
  • c is the polyvinylpyrrolidone concentration (%) in the polyvinylpyrrolidone aqueous solution.
  • K90 is the above formula.
  • the viscosity characteristic value (K value) calculated by applying to (1) is in the range of 81 to 97.2.
  • one kind of polyvinylpyrrolidone may be used alone, or two or more kinds of polyvinylpyrrolidones having different K values may be used in any combination.
  • the concentration of polyvinylpyrrolidone is not particularly limited, but is, for example, 0.001% (w / v) or more, preferably 0.001 to 10% (w / v), more preferably 0. 0.01 to 10% (w / v), more preferably 0.05 to 10% (w / v), even more preferably 0.1 to 10% (w / v), and even more preferably 0.1 to 5 % (W / v), particularly preferably 1-5% (w / v).
  • composition can be further supplemented with pharmaceutically acceptable preservatives as needed.
  • pharmaceutically acceptable preservatives such as silver nitrate, benzalkonium chloride, benzalkonium bromide, benzethonium chloride, chlorhexidine gluconate, boric acid, borax, sorbic acid, potassium sorbate, methyl paraoxybenzoate, propyl paraoxybenzoate, Examples thereof include chlorobutanol, polydronium chloride, and polyhexanide hydrochloride.
  • a preferable preservative in the present invention is a silver salt.
  • silver salts include silver nitrate, silver sulfate, silver chloride, silver bromide, silver oxide, silver acetate, silver carbonate, silver citrate, silver lactate, silver phosphate, silver oxalate, silver thiosulfate, and protein silver.
  • silver nitrate is preferable.
  • the concentration of the silver salt is not particularly limited, and is not particularly limited as long as it is in the range of 0.00000001 to 1% (w / v), for example.
  • the lower limit values are, for example, 0.00000001% (w / v) or more, 0.000000001% (w / v) or more, 0.000001% (w / v) or more, 0.0000025%.
  • the upper limit is, for example, 1% (w / v) or less, 0.5% (w / v) or less, 0.1% (w / v) or less, 0.05% (w / v) or less.
  • 0.01% (w / v) or less, 0.005% (w / v) or less, or 0.001% (w / v) or less is preferable.
  • pharmaceutically acceptable additives can be further added to the composition, if necessary.
  • buffering agents such as sodium phosphate, sodium hydrogen phosphate, sodium hydrogen phosphate hydrate, sodium dihydrogen phosphate, sodium acetate, epsilon-aminocaproic acid; calcium chloride, sodium chloride, potassium chloride, concentrated glycerin, etc.
  • Isotonic agents such as sodium edetate, sodium edetate hydrate, citrate hydrate, sodium citrate hydrate; surfactants such as polysorbate; antioxidants such as ascorbic acid;
  • a thickening agent also referred to as a thickener
  • hydroxyethyl cellulose or hydroxypropyl methyl cellulose such as hydroxyethyl cellulose or hydroxypropyl methyl cellulose
  • a pH adjusting agent such as hydrochloric acid or sodium hydroxide can be selected and added as necessary.
  • the composition does not have to contain a cellulosic polymer which is a thickening agent such as hydroxyethyl cellulose and hydroxypropyl methyl cellulose.
  • the "ophthalmic composition” refers to a composition for use in the prevention and / or treatment of eye diseases and the like.
  • the dosage form include eye drops, eye ointments, injections, ointments (for example, which can be administered to the skin of the eyelids), and the like, and eye drops are preferable.
  • eye drops are synonymous with eye drops or eye drops, and eye drops for contact lenses are also included in the definition of eye drops.
  • the present composition may be a soluble eye drop or a suspension eye drop depending on the properties and contents of the active ingredient and the additive.
  • the composition can be stored in an airtight container, specifically, an eye drop container.
  • an eye drop container filled with the present composition
  • examples of the eye drop container filled with the present composition include a "multi-dose type eye drop container” and a "unit-dose type eye drop container”.
  • the "ophthalmic pharmaceutical product” refers to a product for ophthalmic pharmaceuticals in which the present composition is filled in an eye drop container.
  • examples of the "ophthalmic pharmaceutical product” include eye drop products.
  • the definition of each term in the “ophthalmic pharmaceutical product” of the present invention is the same as the definition of each term in the "composition”.
  • the "multi-dose type eye drop container” is an eye drop container provided with a container body and a cap that can be attached to the container body, and the cap can be freely opened and resealed.
  • the multi-dose type eye drop container usually contains a plurality of doses of eye drops for use for a certain period of time.
  • the composition may be contained in a PFMD (Preservative Free Multi Dose) container.
  • Dry eye symptoms include subjective symptoms such as dry eyes, discomfort, eye fatigue, dullness, photophobia, eye pain, and blurred vision (blurred vision), as well as other symptoms such as congestion and keratoconjunctival epithelial disorders. Findings are also included.
  • "prevention or treatment of dry eye” also includes improvement of the above-mentioned subjective symptoms and / or objective findings.
  • Eye drops B Sterilized purified water containing sodium hydrogen phosphate hydrate (0.2 g), sodium edetate hydrate (0.01 g), sodium chloride (0.45 g), silver nitrate (0.00004 g), and polyvinylpyrrolidone K90 (4 g). The pH was adjusted to 100 mL, and a pH regulator (q.s.) was added to adjust the pH to 7.5.
  • Eye drops X As the eye drop X, "Diquas (registered trademark) eye drop 3%" (manufactured by Santen Pharmaceutical Co., Ltd.), which is used as a therapeutic agent for dry eye, was used.
  • Ophthalmic solution X contains 30 mg of sodium diquafosol as an active ingredient in 1 mL of water, and contains potassium chloride, sodium chloride, chlorhexidine gluconate solution, sodium hydrogen phosphate hydrate, and sodium edetate hydrate as additives. , Contains a pH regulator.
  • Eye drops Y An ophthalmic solution of ophthalmic solution Y was prepared according to the formulation shown in Table 3. Specifically, sodium hydrogen phosphate hydrate (0.2 g), sodium edetate hydrate (0.01 g), sodium chloride (0.45 g), silver nitrate (0.00004 g), sodium diquafosol ( 3 g) was dissolved in sterilized purified water to make 100 mL, and a pH adjuster (q.s.) was added to make pH 7.5.
  • Table 3 sodium hydrogen phosphate hydrate (0.2 g), sodium edetate hydrate (0.01 g), sodium chloride (0.45 g), silver nitrate (0.00004 g), sodium diquafosol ( 3 g) was dissolved in sterilized purified water to make 100 mL, and a pH adjuster (q.s.) was added to make pH 7.5.
  • Eye drops C and D Each eye drop C and D was prepared in the same manner as the eye drop Y according to the formulation shown in Table 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2020/031917 2019-08-27 2020-08-25 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 WO2021039748A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020247011257A KR20240049646A (ko) 2019-08-27 2020-08-25 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
JP2021521065A JP6966667B2 (ja) 2019-08-27 2020-08-25 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
CN202311818685.6A CN117771172A (zh) 2019-08-27 2020-08-25 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物
KR1020227009546A KR102656181B1 (ko) 2019-08-27 2020-08-25 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
CN202080059970.2A CN114286670B (zh) 2019-08-27 2020-08-25 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-154525 2019-08-27
JP2019154525 2019-08-27

Publications (1)

Publication Number Publication Date
WO2021039748A1 true WO2021039748A1 (ja) 2021-03-04

Family

ID=74685901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/031917 WO2021039748A1 (ja) 2019-08-27 2020-08-25 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Country Status (4)

Country Link
JP (2) JP6966667B2 (ko)
KR (2) KR20240049646A (ko)
CN (2) CN117771172A (ko)
WO (1) WO2021039748A1 (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114646705A (zh) * 2022-03-22 2022-06-21 武汉绿合医药科技有限公司 一种地夸磷索钠滴眼液有关物质含量检测方法
WO2022210784A1 (ja) * 2021-03-30 2022-10-06 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
JP7245383B1 (ja) 2022-09-20 2023-03-23 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のｐＨの低下を抑制する方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091795A1 (fr) * 2000-05-30 2001-12-06 Santen Pharmaceutical Co., Ltd. Promoteurs de l'extension de l'epithelium corneen
WO2012090994A1 (ja) * 2010-12-28 2012-07-05 参天製薬株式会社 ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法
WO2016104704A1 (ja) * 2014-12-25 2016-06-30 参天製薬株式会社 水性点眼液
WO2019168023A1 (ja) * 2018-02-28 2019-09-06 参天製薬株式会社 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0365270A (ja) 1989-07-31 1991-03-20 Kanzaki Paper Mfg Co Ltd 塗布シートの製造方法
JPH0365270U (ko) 1989-10-31 1991-06-25
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
KR100549904B1 (ko) * 1996-03-27 2006-05-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 우리딘트리포스페이트및관련화합물을함유하는섬모운동장해치료용약학조성물
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
CN1413114A (zh) * 1999-12-27 2003-04-23 参天制药株式会社 用于稳定泪液层的体系
KR101484499B1 (ko) * 2005-02-14 2015-01-20 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈
CN103096929A (zh) * 2010-09-10 2013-05-08 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂、干眼症的治疗方法、及干眼症治疗剂的应用
KR20120077080A (ko) 2010-12-30 2012-07-10 동우 화인켐 주식회사 광학필름 및 이를 이용한 백라이트 유닛
US20160213708A1 (en) * 2012-01-08 2016-07-28 Medicure Technologies Ltd. Ophthalmic composition
GEP20166470B (en) * 2012-03-26 2016-04-25 Santen Pharmaceutical Co Ltd Diquafosol-containing eye drop
JP2015032653A (ja) 2013-08-01 2015-02-16 株式会社東芝 固体撮像装置
JP6267003B2 (ja) 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
MA39767B1 (fr) * 2014-05-07 2019-10-31 Croma Pharma Ges M B H Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec
TW201707710A (zh) * 2015-06-05 2017-03-01 參天製藥股份有限公司 特徵爲用於滴入戴著軟性隱形眼鏡的乾眼症患者的眼睛之乾眼症治療劑

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091795A1 (fr) * 2000-05-30 2001-12-06 Santen Pharmaceutical Co., Ltd. Promoteurs de l'extension de l'epithelium corneen
WO2012090994A1 (ja) * 2010-12-28 2012-07-05 参天製薬株式会社 ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法
WO2016104704A1 (ja) * 2014-12-25 2016-06-30 参天製薬株式会社 水性点眼液
WO2019168023A1 (ja) * 2018-02-28 2019-09-06 参天製薬株式会社 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOBBELS, MARTIN ET AL.: "Corneal epithelial permeability of dry eyes before and after treatment with artificial tears", OPHTHALMOLOGY, vol. 99, no. 6, 1992, pages 873 - 878, XP009091354 *
KOH, SHIZUKA: "Practical contact lens prescription, D. Regular examination for contact lens, 3. Dry eye treatment when wearing contact lenses", JOURNAL OF THE EYE, vol. 32, 2015, pages 206 - 209 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022210784A1 (ja) * 2021-03-30 2022-10-06 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
JP7175431B1 (ja) * 2021-03-30 2022-11-18 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
JP2023011898A (ja) * 2021-03-30 2023-01-24 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
JP7273235B2 (ja) 2021-03-30 2023-05-12 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
CN114646705A (zh) * 2022-03-22 2022-06-21 武汉绿合医药科技有限公司 一种地夸磷索钠滴眼液有关物质含量检测方法
JP7245383B1 (ja) 2022-09-20 2023-03-23 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のｐＨの低下を抑制する方法
JP2024044960A (ja) * 2022-09-20 2024-04-02 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のｐＨの低下を抑制する方法

Also Published As

Publication number Publication date
KR20240049646A (ko) 2024-04-16
JP2022003099A (ja) 2022-01-11
CN114286670B (zh) 2024-01-16
TW202122094A (zh) 2021-06-16
CN117771172A (zh) 2024-03-29
KR102656181B1 (ko) 2024-04-08
CN114286670A (zh) 2022-04-05
KR20220052971A (ko) 2022-04-28
JPWO2021039748A1 (ja) 2021-09-30
JP6966667B2 (ja) 2021-11-17

Similar Documents

Publication Publication Date Title
WO2021039748A1 (ja) ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
KR102472773B1 (ko) 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물
TWI833913B (zh) 含有迪夸弗索(diquafosol)或其鹽、乙烯系高分子及纖維素系高分子之眼科用組合物
US20210177753A1 (en) Ophthalmic pharmaceutical composition containing a combination of brinzolamide and brimonidine and method of preparation thereof
CN110200904B (zh) 一种降眼压缓释滴眼组合物及其制备方法
CN110913867B (zh) 热凝胶化人工泪液
JP7526718B2 (ja) ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
CA2835013C (en) Eye drops for treatment of conjunctivochalasis
WO2022107791A1 (ja) ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液
EA044372B1 (ru) Офтальмологическая композиция, включающая диквафозол и катионный полимер

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20856231

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021521065

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20227009546

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20856231

Country of ref document: EP

Kind code of ref document: A1